Get the Stockscreener App
0.6979
6.57%
0.043
Briacell Therapeutics Corp stock is traded at $0.6979, with a volume of 803.96K.
It is up +6.57% in the last 24 hours and down -13.30% over the past month.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
See More
Previous Close:
$0.6549
Open:
$0.65
24h Volume:
803.96K
Relative Volume:
0.66
Market Cap:
$13.15M
Revenue:
-
Net Income/Loss:
$-16.60M
P/E Ratio:
-0.7842
EPS:
-0.89
Net Cash Flow:
$-23.48M
1W Performance:
-5.69%
1M Performance:
-13.30%
6M Performance:
-84.21%
1Y Performance:
-94.33%
1-Day Range:
$0.6311
$0.70
1-Week Range:
$0.6311
$0.79
52-Week Range:
$0.61
$29.40
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
0.6979 | 13.39M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
BriaCell announces public offering of common shares - MSN
MACD Signals Flash Warning for BriaCell Therapeutics Corp. Equity Warrant StockWall Street Watch & Fast Gain Stock Trading Tips - 선데이타임즈
Is This the Dip to Buy in BriaCell Therapeutics Corp. Equity Warrant2025 Key Highlights & Fast Moving Market Watchlists - newsyoung.net
Is BriaCell Therapeutics Corp. stock heavily shortedProfit Target & High Win Rate Trade Tips - thegnnews.com
Regression Model Predicts Rangebound Movement in BriaCell Therapeutics Corp. Equity WarrantJuly 2025 Sector Moves & Weekly Market Pulse Alerts - metal.it
Price momentum metrics for BriaCell Therapeutics Corp. explained2025 Short Interest & Real-Time Volume Spike Alerts - Newser
BriaCell Therapeutics Corp. stock daily chart insightsTrade Volume Report & Reliable Intraday Trade Alerts - Newser
How high can BriaCell Therapeutics Corp. Equity Warrant stock goJuly 2025 Gainers & Stepwise Trade Signal Implementation - Newser
Is a relief rally coming for BriaCell Therapeutics Corp. Equity Warrant holdersMarket Growth Summary & Reliable Breakout Stock Forecasts - Newser
Can BriaCell Therapeutics Corp. Equity Warrant hit a new high this monthPortfolio Risk Summary & Daily Volume Surge Signals - Newser
Why BriaCell Therapeutics Corp. Equity Warrant stock attracts strong analyst attentionEarnings Miss & Safe Swing Trade Setups - Newser
Full technical analysis of BriaCell Therapeutics Corp. stockJuly 2025 Market Mood & Real-Time Volume Trigger Notifications - Newser
Detecting support and resistance levels for BriaCell Therapeutics Corp.2025 Top Decliners & Long-Term Safe Investment Plans - Newser
Institutional scanner results for BriaCell Therapeutics Corp.Weekly Trade Recap & High Conviction Investment Ideas - Newser
Using fundamentals and technicals on BriaCell Therapeutics Corp.July 2025 Recap & Safe Capital Growth Stock Tips - Newser
How moving averages guide BriaCell Therapeutics Corp. Equity Warrant tradingPortfolio Growth Summary & Weekly Top Gainers Trade List - Newser
Should you wait for a breakout in BriaCell Therapeutics Corp. Equity WarrantJuly 2025 Action & High Accuracy Trade Signal Alerts - Newser
Can BriaCell Therapeutics Corp. Equity Warrant maintain sales growthDip Buying & Reliable Entry Point Trade Alerts - thegnnews.com
What are BriaCell Therapeutics Corp. Equity Warrant’s earnings expectationsTrade Entry Report & Fast Moving Stock Trade Plans - sundaytimes.kr
Is BriaCell Therapeutics Corp. the Top Chart Pick This WeekQuarterly Portfolio Summary & Verified Technical Signals - sundaytimes.kr
Published on: 2025-08-14 21:54:42 - beatles.ru
Can BriaCell Therapeutics Corp. Escape Recent Bear Channel2025 Volume Leaders & Safe Entry Zone Identification - mustnews.co.kr
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer - GlobeNewswire
BriaCell Joins MSK’s 2025 Therapeutics Accelerator Program - TipRanks
BriaCell's Strategic Alliance with MSK and the Acceleration of Bria-OTS+ as a Game-Changer in Cancer Immunotherapy - AInvest
BriaCell Selected for MSK's 2025 Therapeutics Accelerator Progra - GuruFocus
BriaCell joins Memorial Sloan Kettering’s Therapeutics Accelerator program - Investing.com
BriaCell joins Memorial Sloan Kettering’s Therapeutics Accelerator program By Investing.com - Investing.com Nigeria
BriaCell's Bria-OTS+ accepted into MSK's Therapeutics Accelerator Cohort program. - AInvest
Memorial Sloan Kettering Selects BriaCell's Novel Cancer Immunotherapy for 2025 Development Program - Stock Titan
Will BriaCell Therapeutics Corp. Equity Warrant Sustain Its Chart BreakoutGrowth Based Stock Signal Screener Updated - sundaytimes.kr
BriaCell Shares Slide 22% After Announcing Dilutive Public Offering - MSN
BriaCell Therapeutics To Carry Out 1-for-10 Reverse Stock Split On August 25th, 2025 - 富途牛牛
BriaCell Announces Share Consolidation to Maintain Nasdaq Compliance - The Globe and Mail
BriaCell Announces Proposed Effective Date of Share Consolidation - GlobeNewswire
BriaCell Sets August 25 for Major 10:1 Share Consolidation: What Shareholders Must Know - Stock Titan
My Honest Opinion of Energy Transfer Stock - The Globe and Mail
Simon Property Reports Strong Q2 2025 Financial Results - The Globe and Mail
What institutional investors are buying BriaCell Therapeutics Corp. Equity Warrant stockUnlock powerful stock screening techniques - Jammu Links News
How does BriaCell Therapeutics Corp. compare to its industry peersDiscover high-impact investment opportunities - Jammu Links News
How does BriaCell Therapeutics Corp. Equity Warrant generate profit in a changing economySuperior risk-adjusted returns - Jammu Links News
(BCT) Technical Pivots with Risk Controls (BCT:CA) - news.stocktradersdaily.com
What institutional investors are buying BriaCell Therapeutics Corp. stockDiscover the next big stock winners - Jammu Links News
What makes BriaCell Therapeutics Corp. stock price move sharplyCapitalize on emerging trends for profits - Jammu Links News
How volatile is BriaCell Therapeutics Corp. Equity Warrant stock compared to the marketMassive portfolio appreciation - Jammu Links News
BriaCell Therapeutics Corp. Equity Warrant Stock Analysis and ForecastGet daily updates on promising stocks - Jammu Links News
How does BriaCell Therapeutics Corp. Equity Warrant compare to its industry peersHigh-octane gains - Jammu Links News
What makes BriaCell Therapeutics Corp. Equity Warrant stock price move sharplyUnlock powerful market insights for success - Jammu Links News
What drives BriaCell Therapeutics Corp. Equity Warrant stock priceMaximize returns with data-driven strategies - Jammu Links News
What is the dividend policy of BriaCell Therapeutics Corp. Equity Warrant stockMaximize gains with expert analysis - Jammu Links News
Published on: 2025-08-03 12:02:14 - Jammu Links News
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):